|Application:||Gene expression microarray analysis|
|Number of samples:||12|
|Release date:||Feb 25 2013|
|Last update date:||Aug 23 2018|
|Diseases:||Neoplasms, Neuroblastoma, Hematologic Neoplasms|
|Dataset link||Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition|
JQ1 is a novel thieno-triazolo-1,4-diazepine, which displaces BET bromodomains from chromatin by competitively binding to the acetyl lysine recognition pocket. BE(2)-C and Kelly cells were treated in triplicate with 1 µM JQ1 or DMSO for 24 hours. RNA was extracted and a decrease in MYCN transcript was confirmed by real time RT-PCR as described above. The samples were profiled using the Affymetrix PrimeView Human Gene Expression Array (Affymetrix) at Beth Israel Deaconess Medical Center (Boston, MA, USA).